Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Penelope MacRae
Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.
Astounding plaintiffs, Celgene has backed out of a $55m settlement of a class-action lawsuit which accused the company of monopolizing the market for two top-selling cancer drugs and depriving patients of cheaper generic versions.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
The High Court of Delhi has issued a temporary injunction blocking four Indian drug-makers from launching generic versions of Bristol-Myers’ top-selling anticoagulant apixaban.
Indian companies should post “healthy” growth in 2020, helped by a robust domestic market and abating US pricing pressures, analysts say.
Arun Kumar is stepping down as chief executive of Strides Pharma to focus on overall corporate strategy and the company’s return to injectables. He will be replaced by former Cipla chief operating officer R Ananthanarayanan.